Scienture Holdings, Inc. Common Stock (SCNX) is a publicly traded Healthcare sector company. As of May 21, 2026, SCNX trades at $0.39 with a market cap of $15.99M and a P/E ratio of -0.14. SCNX moved -2.15% today. Year to date, SCNX is -25.14%; over the trailing twelve months it is -57.40%. Its 52-week range spans $0.24 to $9.55. Analyst consensus is buy with an average price target of $1.50. Rallies surfaces SCNX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Scienture Secures 180-Day Nasdaq Compliance Extension and Prepares Q2 REZENOPY Launch: Scienture received a 180-day extension until October 12, 2026 to regain Nasdaq’s $1.00 minimum bid price requirement via a reverse stock split or share price increase. The company cites Arbli™ momentum and plans a Q2 2026 REZENOPY™ nasal spray launch as growth drivers.
| Metric | Value |
|---|---|
| Price | $0.39 |
| Market Cap | $15.99M |
| P/E Ratio | -0.14 |
| EPS | $-2.70 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.55 |
| 52-Week Low | $0.24 |
| Volume | 6.76K |
| Avg Volume | 0 |
| Revenue (TTM) | $431.61K |
| Net Income | $-41.51M |
| Gross Margin | 76.80% |
1 analysts cover SCNX: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $1.50.